MCL-1369: Global Burden and Temporal Trends of Non-Hodgkin Lymphoma: A Global Burden of Disease 2021 Analysis Across 204 Countries

Non-Hodgkin lymphoma (NHL) comprises a heterogeneous group of hematologic malignancies and remains a major contributor to the global cancer burden. Comprehensive global estimates are essential to inform policy and guide cancer control strategies. We analyzed the burden of NHL using the Global Burden of Disease 2021 dataset across 204 countries and territories from 1990 to 2021. Key metrics included disability-adjusted life years (DALYs), years of life lost (YLLs), and prevalence, reported as absolute numbers and age-standardized rates. Data were processed in R (v4.4.2) using tidyverse, ggplot2, and related packages. In 2021, NHL accounted for a total of 7,758,893 DALYs, of which 7,412,577 were attributed to YLLs, reflecting the substantial mortality burden of the disease. The global prevalence was 2,916,574 cases in 2021. Between 1990 and 2021, age-standardized DALY rates showed modest increases, rising from 100.4 per 100,000 in 1990 to 111.7 per 100,000 in 2021. Similarly, age-standardized YLL rates increased from 97.2 to 107.1, while prevalence rates rose from 23.9 to 46.5 per 100,000 during the same period. Geographically, the highest absolute DALYs in 2021 were reported in China, India, and the United States, with China alone contributing over 15% of the global NHL DALY burden. When assessed by percentage share of the global burden, the top contributors remained almost consistent across DALYs, YLLs, and prevalence, with China, the US, India, and Japan at the forefront. Despite diagnostic advances and expanding treatment options, the global burden of NHL has increased over the past three decades. The rising age-standardized DALY and prevalence rates highlight the need for targeted prevention strategies and enhanced access to care, particularly in high-burden countries. Future health policies must account for these evolving trends to alleviate the societal and health care burdens imposed by NHL.

Authors

Institutions

Publication Details

Journal
Clinical Lymphoma Myeloma & Leukemia
Published
2025-08-28
DOI
https://doi.org/10.1016/s2152-2650(25)02484-x
Primary Topic
Multiple and Secondary Primary Cancers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

MCL-1369: Global Burden and Temporal Trends of Non-Hodgkin Lymphoma: A Global Burden of Disease 2021 Analysis Across 204 Countries

Venkatesh Gondhi, Swetha Balaji, Waseem Nabi, Amara Sofia et al.
1 links
Clinical Lymphoma Myeloma & Leukemia
Multiple and Secondary Primary Cancers
article

MCL-1369: Global Burden and Temporal Trends of Non-Hodgkin Lymphoma: A Global Burden of Disease 2021 Analysis Across 204 Countries

Venkatesh Gondhi, Swetha Balaji, Waseem Nabi, Amara Sofia, Muzamil Khan, Nouman Aziz, Amar Lal, Nasir Abu Nasir
article en

Abstract

Non-Hodgkin lymphoma (NHL) comprises a heterogeneous group of hematologic malignancies and remains a major contributor to the global cancer burden. Comprehensive global estimates are essential to inform policy and guide cancer control strategies. We analyzed the burden of NHL using the Global Burden of Disease 2021 dataset across 204 countries and territories from 1990 to 2021. Key metrics included disability-adjusted life years (DALYs), years of life lost (YLLs), and prevalence, reported as absolute numbers and age-standardized rates. Data were processed in R (v4.4.2) using tidyverse, ggplot2, and related packages. In 2021, NHL accounted for a total of 7,758,893 DALYs, of which 7,412,577 were attributed to YLLs, reflecting the substantial mortality burden of the disease. The global prevalence was 2,916,574 cases in 2021. Between 1990 and 2021, age-standardized DALY rates showed modest increases, rising from 100.4 per 100,000 in 1990 to 111.7 per 100,000 in 2021. Similarly, age-standardized YLL rates increased from 97.2 to 107.1, while prevalence rates rose from 23.9 to 46.5 per 100,000 during the same period. Geographically, the highest absolute DALYs in 2021 were reported in China, India, and the United States, with China alone contributing over 15% of the global NHL DALY burden. When assessed by percentage share of the global burden, the top contributors remained almost consistent across DALYs, YLLs, and prevalence, with China, the US, India, and Japan at the forefront. Despite diagnostic advances and expanding treatment options, the global burden of NHL has increased over the past three decades. The rising age-standardized DALY and prevalence rates highlight the need for targeted prevention strategies and enhanced access to care, particularly in high-burden countries. Future health policies must account for these evolving trends to alleviate the societal and health care burdens imposed by NHL.

Clinical Lymphoma Myeloma & LeukemiaVol. 25
George Washington University (US), Wyckoff Heights Medical Center (US), Academic College of Tel Aviv-Yafo (IL), Denso (United States) (US), Penn State Milton S. Hershey Medical Center (US)
Openalex Percentile: Top 69%
Multiple and Secondary Primary Cancers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.